Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.
NEW YORK, Sept 28 (Reuters Breakingviews) - An effective treatment for Alzheimer’s disease has long been the holy grail for drug companies. The $11 billion pop in Biogen’s (BIIB.O), opens new tab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback